查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2048147

生物製藥第三方物流市場－全球產業規模、佔有率、趨勢、機會與預測：按供應鏈、服務類型、地區和競爭對手分類，2021-2031年

Biopharmaceutical Third-party Logistics Market - Global Industry Size, Share, Trends, Opportunity, & Forecast Segmented By Supply Chain, By Service Type, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球生物製藥第三方物流市場預計將從 2025 年的 1,363.6 億美元成長到 2031 年的 2,033.8 億美元，複合年成長率為 6.89%。

該行業專注於生物來源，其特點是將倉儲、庫存管理和溫控運輸等供應鏈管理營運進行專業外包。推動這一成長的關鍵因素包括：對精準低溫運輸管理的迫切需求，以確保高價值、易損生物製藥的療效；以及製造商為最大限度減少對非核心物流資產的資本投入而採取的戰略舉措。此外，隨著醫藥貿易日益全球化，對能夠有效管理複雜跨境運輸路線的強大分銷網路的需求也日益成長。

市場概覽
預測期 2027-2031
市場規模：2025年 1363.6億美元
市場規模：2031年 2033.8億美元
複合年成長率：2026-2031年 6.89%
成長最快的細分市場 低溫運輸
最大的市場 北美洲

根據醫療保健分銷聯盟 (HDA) 預測，美國藥品批發商2024年的銷售額預計將達到8,620億美元，年增10.4%。這一顯著成長反映出醫療保健系統對中間物流供應商的依賴性日益增強。儘管有這些正面趨勢，但新興地區基礎設施不足仍然是市場成長的主要障礙。不可靠的低溫運輸設施會威脅產品質量，並阻礙市場的順利擴張。

市場促進因素

生物製藥和生物相似藥的激增是推動市場發展的主要催化劑，催生了對高精度供應鏈解決方案的需求，而這些解決方案已超出傳統物流網路的能力範圍。隨著製藥公司從化學合成的小分子藥物轉向以大分子藥物作為治療藥物，需要嚴格監管鏈管理的溫控產品數量正急劇成長。這種營運模式的轉變迫使製造商將業務外包給擁有可擴展基礎設施和監管認證的第三方物流(3PL) 供應商，以便在不影響品質的前提下管理不斷成長的生技藥品數量。諾和諾德於 2025 年 2 月發布的 2024 年年度報告突顯了這項變化的規模。該報告指出，其高度依賴溫控配送的糖尿病和肥胖症治療業務的銷售額成長了 26%，達到 2,718 億丹麥克朗，凸顯了對能夠大規模處理複雜庫存的專業合作夥伴的需求。

同時，對低溫運輸物流日益成長的需求迫使該行業利用專業的第三方服務來管理全球溫控運輸中固有的風險。跨境運輸中維持特定溫度範圍（例如 2 度C至 8 度C）或極低冷凍水平的難度，促使製造商與物流整合商合作，以確保產品從頭到尾的完整性。根據國際航空運輸協會 (IATA) 於 2025 年 1 月發布的《航空貨運市場分析》，作為時效性藥品的重要通路，全球航空貨運需求在 2024 年成長了 11.3%，創歷史新高。 DHL 集團的案例進一步印證了這種對專業仲介業者的依賴。該集團在 2025 年發布的報告中指出，其生命科學與醫療保健部門在 2024 會計年度的營收約為 50 億歐元，凸顯了外包物流在全球供應鏈中的關鍵作用。

市場挑戰

全球生物製藥第三方物流市場發展面臨的主要障礙之一是新興地區基礎設施嚴重不足。由於生物製藥需要嚴格的溫度控制，許多發展中市場普遍存在的電力供應不穩定、專業倉儲設施不足以及末端配送網路分散等問題，都構成了嚴重的挑戰。即使運輸過程中溫度出現輕微波動，也可能影響高價值生物製藥的安全性和有效性，直接阻礙市場成長。因此，物流供應商在這些地區面臨更高的責任風險和更低的營運效率，往往迫使生產商將分銷範圍限制在物流基礎設施完善的地區。

物流負擔因需要空運的貨物量不斷增加而加劇，而空運又是運輸對溫度敏感的藥品的主要方式。根據國際航空運輸協會（IATA）2025年的數據，2024年全球航空貨運需求年增11.3%。貨運量的激增給新興市場本已脆弱的供應鏈帶來了巨大壓力。如果當地基礎設施不穩定，無法在嚴格的低溫運輸條件下應對如此龐大的貨運量，該行業將面臨嚴重的瓶頸，限制收入潛力並延誤基本藥物的交付。

市場趨勢

直接面向患者（DTP）的臨床試驗物流模式的擴展，透過分散供應鏈並將臨床實驗藥物直接送達受試者家中，正在改變物流行業格局。這與傳統的基於設施的模式截然不同，要求物流供應商建立精細化的「最後一公里」解決方案，以確保每次配送都得到嚴格的儲存和溫度控制。對這些專業服務的需求正在為投資於醫療保健網路的大型整合商帶來可觀的收入。根據《運輸專題》（Transport Topics）2025年1月的一份報告顯示，聯邦快遞公司（FedEx Corporation）已獲得與醫療保健相關合約將在2024會計年度帶來超過5億美元的收入，這表明這些複雜的物流運營的商業性價值正在不斷成長。

同時，隨著製藥公司致力於減少範圍3排放，採用永續的綠色物流和包裝正成為一項重要的營運標準。物流供應商擴大使用永續航空燃料（SAF）和可重複使用的保溫包裝系統，以減少高能耗低溫運輸運輸相關的碳足跡。這些為實現脫碳而進行的合作努力正在為產業帶來可衡量的環境效益。根據勃林格殷格翰2025年4月發布的報告，該公司與德迅集團合作，在其藥品空運中實施永續航空燃料，僅一年就減少了約8,000噸二氧化碳排放。這正是綠色舉措對全球供應鏈產生實質影響的典型例子。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：生物製藥第三方物流的全球市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 按類型分類的供應鏈（低溫運輸、非低溫運輸）
    • 服務類型（運輸、倉儲/儲存、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美生物製藥第三會物流市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲生物製藥第三方物流市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區生物製藥第三方物流市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲生物製藥第三方物流市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲生物製藥第三方物流市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球生物製藥第三方物流市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • DHL International GmbH.
  • SF Express Co.
  • United Parcel Service of America, Inc.
  • AmerisourceBergen Corporation
  • DB Schenker
  • Kuehne and Nagel AG
  • Kerry Logistics Network Ltd.
  • Agility Co

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 19469

The Global Biopharmaceutical Third-party Logistics Market is projected to expand from USD 136.36 Billion in 2025 to USD 203.38 Billion by 2031, registering a CAGR of 6.89%. This sector is defined by the specialized outsourcing of supply chain management tasks, such as warehousing, inventory oversight, and temperature-controlled transportation, tailored specifically for biologic medicines originating from living organisms. Key factors driving this growth include the critical need for precise cold-chain management to maintain the efficacy of sensitive, high-value biologics, alongside the strategic push for manufacturers to minimize capital spending on non-core logistical assets. Furthermore, the rising globalization of pharmaceutical trade demands resilient distribution networks that can effectively manage complex, cross-border transit routes.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 136.36 Billion
Market Size 2031USD 203.38 Billion
CAGR 2026-20316.89%
Fastest Growing SegmentCold Chain
Largest MarketNorth America

According to the Healthcare Distribution Alliance, pharmaceutical distributors in the United States achieved $862 billion in sales during 2024, marking a 10.4 percent rise from the previous year. This significant growth highlights the increasing dependence on intermediary logistics providers within the healthcare system. Despite this positive trend, the market encounters a major obstacle due to infrastructural inconsistencies in emerging regions, where unreliable cold-chain facilities threaten product integrity and hinder seamless market expansion.

Market Driver

The surge in biologics and biosimilars acts as a primary market catalyst, creating a demand for high-precision supply chain solutions that exceed the capabilities of traditional logistics networks. As pharmaceutical developers transition from chemically synthesized small molecules to large-molecule therapies, there has been a significant rise in the volume of temperature-sensitive products requiring strict chain-of-custody protocols. This operational evolution compels manufacturers to outsource to third-party logistics (3PL) providers equipped with the scalable infrastructure and regulatory certifications necessary to manage growing biologic throughput without sacrificing quality. The magnitude of this shift is highlighted by Novo Nordisk's 'Annual Report 2024' from February 2025, which noted that sales in its Diabetes and Obesity care segments-areas heavily dependent on temperature-controlled distribution-rose by 26% to DKK 271.8 billion, underscoring the need for specialized partners to handle complex inventory at scale.

Concurrently, the rising demand for cold chain logistics forces the industry to utilize specialized third-party services to manage the risks inherent in global temperature-controlled transport. The difficulty of maintaining specific temperature ranges, such as 2°C to 8°C or deep-frozen cryogenic levels during cross-border shipping, leads manufacturers to collaborate with logistics integrators who can guarantee product integrity from start to finish. According to the International Air Transport Association's (IATA) 'Air Cargo Market Analysis' from January 2025, global air cargo demand-a vital channel for time-sensitive pharmaceuticals-grew by 11.3% in 2024, surpassing prior records. This dependence on specialized intermediaries is further evidenced by DHL Group, which reported in 2025 that its Life Sciences & Healthcare unit generated roughly €5 billion in revenue during the 2024 fiscal year, emphasizing the essential role of outsourced logistics in the global supply chain.

Market Challenge

A major obstacle hindering the Global Biopharmaceutical Third-party Logistics Market is the significant lack of robust infrastructure in emerging regions. Since biologics demand strict temperature adherence, the inconsistent electricity supply, inadequate specialized warehousing, and fragmented last-mile delivery networks found in many developing markets present serious issues. This infrastructural deficit directly impedes market growth, as even minor temperature deviations during transit can render high-value biologic shipments unsafe or ineffective. As a result, logistics providers encounter increased liability risks and operational inefficiencies in these territories, often forcing manufacturers to restrict their distribution to regions with established capabilities.

This logistical strain is intensified by the growing volume of goods requiring air transit, a key mode for transporting sensitive pharmaceuticals. Data from the International Air Transport Association in 2025 reveals that global air cargo demand rose by 11.3 percent throughout 2024 compared to the prior year. This rapid increase in cargo volume exerts immense pressure on the already fragile supply chains within emerging markets. When inconsistent local infrastructure fails to handle this increased throughput under rigorous cold-chain conditions, the industry faces severe bottlenecks that limit revenue potential and delay the delivery of essential therapies.

Market Trends

The growth of Direct-to-Patient (DTP) Clinical Trial Distribution is transforming the logistics sector by decentralizing supply chains to deliver investigational medicinal products directly to participants' homes. This moves away from traditional site-based models, requiring logistics providers to establish high-touch, last-mile solutions that guarantee strict chain-of-custody and temperature control for individual deliveries. The demand for such specialized services is generating substantial revenue for major integrators investing in healthcare-specific networks. As reported by Transport Topics in January 2025, FedEx Corp. secured healthcare contracts yielding over $500 million in revenue during the 2024 fiscal year, illustrating the rising commercial value of these complex logistics operations.

Simultaneously, the adoption of Sustainable Green Logistics and Packaging is becoming a vital operational standard as pharmaceutical companies aim to lower their Scope 3 emissions. Logistics providers are increasingly utilizing Sustainable Aviation Fuel (SAF) and reusable thermal packaging systems to reduce the carbon footprint linked to energy-intensive cold chain transport. These collaborative decarbonization efforts are producing measurable environmental advantages for the industry. According to an April 2025 report from Boehringer Ingelheim, the company's collaboration with Kuehne+Nagel to use SAF for pharmaceutical air freight led to a reduction of roughly 8,000 tons of CO2 emissions in a single year, showcasing the tangible impact of green initiatives on the global supply chain.

Key Market Players

  • DHL International GmbH.
  • SF Express Co.
  • United Parcel Service of America, Inc.
  • AmerisourceBergen Corporation
  • DB Schenker
  • Kuehne and Nagel AG
  • Kerry Logistics Network Ltd.
  • Agility Co

Report Scope

In this report, the Global Biopharmaceutical Third-party Logistics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Biopharmaceutical Third-party Logistics Market, By Supply Chain

  • Cold Chain
  • Non-cold Chain

Biopharmaceutical Third-party Logistics Market, By Service Type

  • Transportation
  • Warehousing & Storage
  • Other

Biopharmaceutical Third-party Logistics Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Biopharmaceutical Third-party Logistics Market.

Available Customizations:

Global Biopharmaceutical Third-party Logistics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Biopharmaceutical Third-party Logistics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Supply Chain (Cold Chain, Non-cold Chain)
    • 5.2.2. By Service Type (Transportation, Warehousing & Storage, Other)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Biopharmaceutical Third-party Logistics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Supply Chain
    • 6.2.2. By Service Type
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Biopharmaceutical Third-party Logistics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Supply Chain
        • 6.3.1.2.2. By Service Type
    • 6.3.2. Canada Biopharmaceutical Third-party Logistics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Supply Chain
        • 6.3.2.2.2. By Service Type
    • 6.3.3. Mexico Biopharmaceutical Third-party Logistics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Supply Chain
        • 6.3.3.2.2. By Service Type

7. Europe Biopharmaceutical Third-party Logistics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Supply Chain
    • 7.2.2. By Service Type
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Biopharmaceutical Third-party Logistics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Supply Chain
        • 7.3.1.2.2. By Service Type
    • 7.3.2. France Biopharmaceutical Third-party Logistics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Supply Chain
        • 7.3.2.2.2. By Service Type
    • 7.3.3. United Kingdom Biopharmaceutical Third-party Logistics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Supply Chain
        • 7.3.3.2.2. By Service Type
    • 7.3.4. Italy Biopharmaceutical Third-party Logistics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Supply Chain
        • 7.3.4.2.2. By Service Type
    • 7.3.5. Spain Biopharmaceutical Third-party Logistics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Supply Chain
        • 7.3.5.2.2. By Service Type

8. Asia Pacific Biopharmaceutical Third-party Logistics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Supply Chain
    • 8.2.2. By Service Type
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Biopharmaceutical Third-party Logistics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Supply Chain
        • 8.3.1.2.2. By Service Type
    • 8.3.2. India Biopharmaceutical Third-party Logistics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Supply Chain
        • 8.3.2.2.2. By Service Type
    • 8.3.3. Japan Biopharmaceutical Third-party Logistics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Supply Chain
        • 8.3.3.2.2. By Service Type
    • 8.3.4. South Korea Biopharmaceutical Third-party Logistics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Supply Chain
        • 8.3.4.2.2. By Service Type
    • 8.3.5. Australia Biopharmaceutical Third-party Logistics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Supply Chain
        • 8.3.5.2.2. By Service Type

9. Middle East & Africa Biopharmaceutical Third-party Logistics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Supply Chain
    • 9.2.2. By Service Type
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Biopharmaceutical Third-party Logistics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Supply Chain
        • 9.3.1.2.2. By Service Type
    • 9.3.2. UAE Biopharmaceutical Third-party Logistics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Supply Chain
        • 9.3.2.2.2. By Service Type
    • 9.3.3. South Africa Biopharmaceutical Third-party Logistics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Supply Chain
        • 9.3.3.2.2. By Service Type

10. South America Biopharmaceutical Third-party Logistics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Supply Chain
    • 10.2.2. By Service Type
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Biopharmaceutical Third-party Logistics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Supply Chain
        • 10.3.1.2.2. By Service Type
    • 10.3.2. Colombia Biopharmaceutical Third-party Logistics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Supply Chain
        • 10.3.2.2.2. By Service Type
    • 10.3.3. Argentina Biopharmaceutical Third-party Logistics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Supply Chain
        • 10.3.3.2.2. By Service Type

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Biopharmaceutical Third-party Logistics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. DHL International GmbH.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. SF Express Co.
  • 15.3. United Parcel Service of America, Inc.
  • 15.4. AmerisourceBergen Corporation
  • 15.5. DB Schenker
  • 15.6. Kuehne and Nagel AG
  • 15.7. Kerry Logistics Network Ltd.
  • 15.8. Agility Co

16. Strategic Recommendations

17. About Us & Disclaimer